Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: We report the clinical activity and safety of bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β)RII receptor (a TGF-β ‘trap’) fused to a human IgG1 monoclonal antibody blocking programmed death-ligand 1 (PD-L1), in patients with heavily pretreated squamous cell carcinoma of the head and neck (SCCHN). Methods: In this phase I dose-expansion cohort, patients with advanced SCCHN not amenable to curative therapy that progressed/recurred after platinum therapy in the recurrent/metastatic setting, or <6 months after platinum therapy in the locally advanced setting, received bintrafusp alfa 1200 mg intravenously every 2 weeks. The primary endpoint was confirmed best overall response (BOR; Response Evaluation Criteria for Solid Tumors (RECIST) 1.1) per independent review committee (IRC); other endpoints included BOR per investigator and safety. Results: As of August 24, 2018, 32 patients had received bintrafusp alfa (median follow-up 86.4 weeks; range 2–97). Per IRC, the confirmed objective response rate (ORR) was 13% (95% CI 4% to 29%; 4 partial responses (PR)); 4 patients had stable disease (SD) (disease control rate 34%; 95% CI 19% to 53%). Per investigator, there were 5 PRs (ORR, 16%), including 2 patients who developed delayed PRs after initial disease increase (total clinical response rate 22%). Responses (ORRs) were observed in patients with PD-L1-positive (12%), PD-L1-negative (17%; 73-10 antibody for immunohistochemistry), human papillomavirus (HPV)-positive (33%) and HPV-negative tumors (5%). Grade 3 treatment-related adverse events (TRAEs) were reported in 11 patients (34%), with no grade 4 TRAEs or treatment-related deaths. Conclusions: Bintrafusp alfa showed clinical activity across subgroups of PD-L1 expression and in HPV-positive tumors and had a manageable safety profile in patients with heavily pretreated advanced SCCHN. Activity in HPV-positive tumors is favorable compared with historical data from PD-L1 inhibitors and is being further investigated in an ongoing study of HPV-associated tumors. Trial registration number: NCT02517398.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Near-optimal probabilistic RNA-seq quantification
Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3519 · Cited by 9,723
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 1×
“Exploratory endpoints included PFS, duration of response (DOR) and disease control rate (DCR) according to RECIST 1.1 as adjudicated by IRC, and OS.”
InfluentialElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · cited 7×
“By investigator assessment, ORR and DCR were 16% and 34%, respectively (table 2).”
InfluentialTargeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466 · cited 1×
“Exploratory biomarker analyses of efficacy were also performed.”
MethodStrauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406
Self-citationDavid, J. M., Dominguez, C., McCampbell, K. K., Gulley, J. L., Schlom, J., & Palena, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1349589 · Cited by 180
Self-citation
Research works printed but not linked: 29
- 10.1002/ijc.29210 · DOI · Paper page
- 10.1093/aje/kwp222 · DOI · Paper page
- 10.1200/JCO.2015.61.6995 · DOI · Paper page
- Chow, 2016, Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort, J Clin Oncol, 34, 3838, 10.1200/JCO.2016.68.1478 · DOI · Paper page
- 10.1056/NEJMoa0802656 · DOI · Paper page
- 10.1016/S0140-6736(18)31999-8 · DOI · Paper page
- Grégoire, 2010, Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21 Suppl 5, v184, 10.1093/annonc/mdq185 · DOI · Paper page
- 10.1016/S1470-2045(15)70124-5 · DOI · Paper page
- Kushwaha, 2015, Gefitinib, methotrexate and methotrexate plus 5-fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma, Cancer Biol Ther, 16, 346, 10.4161/15384047.2014.961881 · DOI
- 10.1200/JCO.2006.06.7447 · DOI · Paper page
- 10.1200/JCO.2005.07.119 · DOI · Paper page
- 10.1200/JCO.2005.05.3348 · DOI · Paper page
- 10.1158/1078-0432.CCR-14-1756 · DOI
- 10.1016/S0140-6736(00)90011-0 · DOI · Paper page
- 10.1200/JCO.2016.70.1524 · DOI · Paper page
- 10.1158/1078-0432.CCR-07-1157 · DOI · Paper page
- Gilbert, 2015, A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma, Oral Oncol, 51, 376, 10.1016/j.oraloncology.2014.12.011 · doi:10.1016/j.oraloncology.2014.12.011
- 10.1158/1078-0432.CCR-09-2877 · DOI
- 10.1158/1078-0432.CCR-17-1904 · doi:10.1158/1078-0432.ccr-17-1904
- 10.1158/0008-5472.CAN-14-0602-T · DOI
- 10.1634/theoncologist.2016-0433 · DOI
- 10.1126/scitranslmed.aan5488 · DOI · Paper page
- Strauss, 2018, Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers, JCO, 36, 10.1200/JCO.2018.36.15_suppl.3007 · DOI
- Vugmeyster, 2018, Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1, JCO, 36, 10.1200/JCO.2018.36.15_suppl.2566 · doi:10.1200/jco.2018.36.15_suppl.2566
- 10.1038/nmeth.1923 · DOI · Paper page
- 10.1186/1471-2105-12-323 · DOI · Paper page
- Shankaran, 2015, Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475), Journal of Clinical Oncology, 33, 10.1200/jco.2015.33.15_suppl.3026 · DOI
- 10.1038/s41416-018-0131-9 · DOI · Paper page
- 10.1158/1078-0432.CCR-18-3944 · DOI · Paper page
Cited by
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Recent advances in therapeutic strategies for triple-negative breast cancer
Li, Y., Zhang, H., Merkher, Y., Chen, L., Liu, N., Leonov, S., & Chen, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01341-0 · Cited by 956
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413
Modulating extracellular matrix stiffness: A strategic approach to boost cancer immunotherapy
Mai, Z., Lin, Y., Lin, P., Zhao, X., & Cui, L. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06697-4 · Cited by 398
Overcoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377
Metadata
- Authors
- Cho, B. C., Daste, A., Ravaud, A., Salas, S., Isambert, N., McClay, E., Awada, A., Borel, C., Ojalvo, L. S., Helwig, C., Rolfe, P. A., Gulley, J. L., & Penel, N.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2020-07
- Volume
- 8
- Issue
- 2
- Pages
- e000664
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W3038704019
- Cited by
- 90
- References
- 9
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- GlaxoSmithKline
- Merck KGaA, Darmstadt, Germany
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. https://app.cochat.ai/papers/10.1136/jitc-2020-000664
- The paper
- Cho, B. C., Daste, A., Ravaud, A., Salas, S., Isambert, N., McClay, E., Awada, A., Borel, C., Ojalvo, L. S., Helwig, C., Rolfe, P. A., Gulley, J. L., & Penel, N. (2020). Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-000664
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.